Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

Phase 3WithdrawnNCT03532022

Neurocrine UK Limited

Overview

This study is an open-label, randomised, titration-blinded, parallel arm, multicenter study to compare twice daily Chronocort® with standard care in participants with Congenital Adrenal Hyperplasia (CAH). This study will be conducted in the USA.

It will compare the efficacy, safety and tolerability of twice daily Chronocort® with standard care (using the participant's usual individualized standard glucocorticoid regimen) over a treatment period of 52 weeks in participants aged 16 years and over with known CAH due to 21-hydroxylase deficiency (classic CAH) diagnosed in childhood with documented (at any time) elevated 17-OHP or A4 and currently treated with hydrocortisone, prednisone, prednisolone or dexamethasone (or a combination of the aforementioned glucocorticoids).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Congenital Adrenal Hyperplasia

Interventions

Chronocort®DRUG

Hydrocortisone modified release capsules - 5mg, 10mg and 20mg.

Standard CareDRUG

The subject's standard care regimen upon entering the study; this could consist of hydrocortisone, dexamethasone, prednisone or prednisolone.

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply (note: if a participant fails to meet an inclusion criterion, re-screening is permitted if the Investigator considers that the circumstances leading to screening failure will not be relevant when the participant is re-screened at a later time): Age 1. Participant must be aged 16 years or older at the time of signing the informed consent. 2. In participants aged \<18 years, height velocity must be less than 2 cm in the last year and puberty must be completed. Type of Participant and Disease Characteristics 3. Participants with known CAH due to 21-hydroxylase deficiency (classic CAH) diagnosed in childhood with documented (at any time) elevated 17-OHP or A4 and currently treated with hydrocortisone, prednisone, prednisolone or dexamethasone (or a combination of the aforementioned glucocorticoids). Sex 4. Male and female participants 1. Male participants: \- A male participant must agree to use contraception as detailed in Section 10.4 of this protocol during the treatment period and refrain from donating sperm during this period. 2. Female participants: * A female participant is eligible to participate if she is not pregnant (Section 10.4), not breastfeeding, and at least one of the following conditions applies: i. Not a woman of childbearing potential (WOCBP) as defined in Section 10.4. OR ii. A WOCBP with a negative pregnancy test at entry into the study who agrees to follow the contraceptive guidance in Section 10.4 during the treatment period. Note: females presenting with oligomenorrhea or amenorrhea who are aged ≤55 years should be considered potentially fertile and therefore, as well as undergoing pregnancy testing like all other female participants, will be expected to be using an acceptable method of contraception which should have been ongoing for ≥90 days prior to the study. Informed Consent 5. Capable of giving signed informed consent as described in Section 10.1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply (note: if a participant meets an exclusion criterion, re-screening is permitted if the Investigator considers that the circumstances leading to screening failure will not be relevant when the participant is re-screened at a later time): Medical Conditions 1. Clinical or biochemical evidence of hepatic or renal disease e.g. creatinine \> 2 times the upper limit of normal (ULN) or elevated liver function tests (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\] \>2 times the ULN). 2. History of bilateral adrenalectomy. 3. History of malignancy (other than basal cell carcinoma successfully treated \>26 weeks prior to entry into the study). 4. Participants who have type 1 diabetes or any participant who is receiving insulin. 5. Participants with any other significant medical or psychiatric conditions that in the opinion of the Investigator would preclude participation in the study. Prior/Concomitant Therapy 6. Participants on regular daily oral steroids for any indication other than CAH. Note: a participant should not be given any steroids (even on an irregular basis) within 5 days of a study visit. If there is a medical need for steroid treatment within this time frame then the visit should be postponed until a 5-day interval has elapsed. 7. Co-morbid condition requiring daily administration of a medication or consumption of any material that interferes with the metabolism of glucocorticoids (examples provided at http://medicine.iupui.edu/clinpharm/ddis/clinical-table/). 8. Participants who are receiving \<10 mg hydrocortisone dose at baseline or the hydrocortisone dose equivalent. Prior/Concurrent Clinical Study Experience 9. Participation in another clinical study of an investigational or licensed drug or device within the 12 weeks prior to screening or during the study. 10. Inclusion in any natural history or translational research study that would require evaluation of androgen levels during the study period outside of this study protocol assessments. 11. Participants who have previously been exposed to Chronocort in studies DIUR-003, DIUR-005 or DIUR-006. Other Exclusions 12. Participants who routinely work night shifts and so do not sleep during the usual night-time hours. 13. Participants unable to comply with the requirements of the protocol.

Locations (1)

Diabetes and Endocrinology Consultants PC

Morehead City, North Carolina, United States

Outcomes

Primary Outcomes

Non-inferiority of Chronocort® versus standard care in terms of responder rate.

The proportion of participants after 52 weeks of treatment in the Chronocort® and standard care treatment groups achieving biochemical control. Participants with 17 OHP and A4 in the optimal (for 17-OHP) and reference range (for A4) at both timepoints of 09:00 and 13:00 hours will be classified as 'in biochemical control'; if at least one of these measurements is outside of the optimal (for 17-OHP) or reference range (for A4) they will be classified as 'not in biochemical control'.

Time frame: 52 weeks

Secondary Outcomes

Impact of both treatments on markers of fertility.

Proportion of participants who are "responders" at Weeks 26 and 52 i.e. restoration of menses/more regular menses in women (patient diary used to record menstrual cycle details in pre menopausal women who have not had a hysterectomy and are not using hormonal contraception), and luteinizing hormone (LH) in men that was outside the normal range at baseline but moves to within the normal range during the study

Time frame: Weeks 26 & 52

Impact of both treatments on hirsutism in female participants.

Change in hirsutism will be assessed at Weeks 26 and 52 using a 10 cm VAS ranging from 'No Symptoms' to 'Very Severe Symptoms' which will be completed by the participant.

Time frame: Weeks 26 & 52

Impact of both treatments on acne.

Change in acne assessed at Weeks 26 and 52 using a 10 cm visual analogue scale (VAS) ranging from 'No Symptoms' to 'Very Severe Symptoms' which will be completed by the participant.

Time frame: Weeks 26 & 52

Impact of both treatments on glycated hemoglobin (HbA1c) levels.

Change from baseline to Weeks 26 and 52 in glycated hemoglobin (HbA1c) levels.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Time frame: Weeks 26 & 52

Impact of both treatments on waist circumference (in centimetres).

Change from baseline to Weeks 26 and 52 in waist circumference (cm).

Time frame: Weeks 26 & 52

Impact of both treatments on body weight (in kilograms).

Change from baseline to Weeks 26 and 52 in body weight (kg).

Time frame: Weeks 26 & 52

Impact of both treatments on quality of life (QoL) using SF-36® total score and the sub-domain of vitality.

Change from baseline to Weeks 26 and 52 in Quality of Life using SF-36® total score and the score for the vitality sub-domain.

Time frame: Weeks 26 & 52

Impact of both treatments on Quality of Life using Multidimensional Assessment of Fatigue (MAF).

Change from baseline to Weeks 26 and 52 in Quality of Life using Multidimensional Assessment of Fatigue (MAF).

Time frame: Weeks 26 & 52

Impact of both treatments on Quality of Life using EQ-5D™.

Change from baseline to Weeks 26 and 52 in Quality of Life using EQ-5D™.

Time frame: Weeks 26 & 52

Safety and tolerability of Chronocort® relative to standard care

Incidence of clinical AEs, with a particular focus on adrenal crises.

Time frame: 52 weeks

The need for additional glucocorticoid doses

Use of immediate release hydrocortisone from the sick day packs or use of any additional glucocorticoid treatment during the study.

Time frame: 52 weeks

Safety of Chronocort® compared to standard care by assessment of routine safety haematology assessments - Red blood cell count and platelet count

Routine haematology assessments to compare red blood cell and platelet counts (absolute values) between the Chronocort arm and Standard Care arm.